D 75N95023Q00330 CSS.pdf

COMBINED SYNOPSIS / SOLICITATION

75N95023Q00330

TITLE: iPSC derived Dopaminergic and Glutametrgic Neuronal Cells

(i) THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS

SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING

FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the

National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing full and open competition to Fujifilm Cellular Dynamics, Inc., 525 Science Dr., Madison, WI 53711. NCATS has been using iPSC derived Dopaminergic and Glutametrgic Neuronal Cells from Fujifilm Cellular Dynamics, Inc. for this project and must use these required cells from Fujfilm to ensure uniform data and the continuity of science. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1).

(ii) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice.

This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued.

(iii) The solicitation number is 75N95023Q00330 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 - Simplified Acquisition Procedures and FAR Part 12 - Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

(iv) The solicitation document and incorporated provisions and clauses are those in effect through

Federal Acquisition Circular (FAC) 2023-02 effective March 16, 2023.

(v) The associated NAICS code is 325414 and the Small Business size standard is 1,250 employees.

DESCRIPTION

(vi) The National Center for Advancing Translational Sciences (NCATS), within the National

Institutes of Health (NIH), requires the iPSC derived Dopaminergic and Glutametrgic Neuronal Cells listed below:

1. iCell DopaNeurons, 01279 [Cell Only]. Cat. No# C1028; Over 5M viable cells /vials.

Qty: 10 each.

2. iCell GlutaNeurons, 01279 [Cell Only]. Cat. No# C1033; Over 6M viable cells /vials.

Qty: 21 each.

(vii) The Government anticipates award of a firm, fixed-price purchase order with an anticipated delivery date of 10 days after receipt of order.

EVALUATION AND AWARD

(viii) The anticipated award date is May 30, 2023.

(ix) The Government plans to make an award resulting from this solicitation. The resulting award will be made to Fujifilm Cellular Dynamics, Inc. as long as the quote is technically acceptable and the negotiated price is fair and reasonable.

SUBMISSION INSTRUCTIONS

(x) All responses to this RFQ must be received by 9:00am Eastern Time on Friday, May 26, 2023 and must reference the solicitation number cited above. Responses must be submitted via email to Kimberly Espinosa at kimberly.espinosa@nih.gov.

(xi) This is an RFQ. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or service.

Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this RFQ must be completed by the quoter.

(xii) Responses to this RFQ must include clear and convincing evidence of the quoter’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. Responses may exceed capability or performance characteristics of the solicitation's requirements. The Government reserves the right, but is not required, to award to a response that exceeds capability or performance characteristics of the solicitation's requirements if it provides a benefit to the Government.

(xiii) Responses must include the Unique Entity Identifier (UEI) (which recently replaced the DUNS number), the Taxpayer Identification Number (TIN), the certification of business size, the completed certification in FAR Provision 52.225-2 (attached), and the completed representations in FAR Provision 52.212-3 (attached). If the quoter’s representations in the System for Award Management (SAM) are accurate, only Paragraph B of FAR Provision 52.225-3 should be completed.

(xiv) Responses must also include a quotation in U.S. dollars that includes:

mailto:kimberly.espinosa@nih.gov

1. The total price,

2. Individual prices for each item,

3. Prompt payment discount terms,

4. Product or catalog number(s),

5. Product description, and

6. Any other information or factors that may be considered in the award decision. Such factors may include: special features required for effective program performance; trade-in considerations; warranty considerations; maintenance availability; and environmental and energy efficiency considerations.

(xv) For information about this RFQ, contact Kimberly Espinosa, Contracting Officer, at 301-827-

3546 or kimberly.espinosa@nih.gov.

(xvi) All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.

TERMS AND CONDITIONS, PROVISIONS, AND REPRESENTATIONS

(xvii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb

1998). This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at www.acquisition.gov.

The following provisions apply to this acquisition and are incorporated by reference:

1. FAR Provision 52.204-7, System for Award Management (Oct 2018)

2. FAR Provision 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020)

3. FAR Provision 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services (Dec 2022)

(xviii) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998). This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at www.acquisition.gov.

In addition to the clauses checked in FAR 52.212-5 (attached), the following clauses also apply to this acquisition and are incorporated by reference:

1. FAR Clause 52.204-13, System for Award Management Maintenance (Oct 2018)

2. FAR Clause 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020)

3. FAR Clause 52.212-4, Contract Terms and Conditions – Commercial Products and Commercial Services (Dec 2022)

4. HHSAR Clause 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015)

(xix) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement.

ATTACHMENTS

(xx) The following terms, provisions, and clauses are incorporated and attached in full text:

1. The provision at FAR 52.212-1, Instructions to Offerors – Commercial Products and Commercial Services (Mar 2023) (Tailored)

2. FAR Provision 52.225-2, Buy American Certificate (Oct 2022)

3. FAR Provision 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services (Dec 2022)

4. The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement

Statutes or Executive Orders–Commercial Products and Commercial Services (Mar 2023)

5. NIH Electronic Invoice Submission Instructions with IPP (March 21, 2023)